Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer

Summary

The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.

Interventions

• ctDNA · DIAGNOSTIC_TEST

  ctDNA guided surveillance

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
* Sub-study 2: .

  * PDAC tumor stage I-III
  * Has received intended curative resection (R0/R1) of PDAC
  * No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation

Exclusion Criteria:

* Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
* Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study

Sites (5)

• Aalborg Universitetshospital, Aalborg, Denmark · RECRUITING
• Aarhus Universitetshospital, Aarhus, Denmark · RECRUITING
• Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark · RECRUITING
• Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark · RECRUITING
• Odense Universitetshospital, Odense, Denmark · RECRUITING